GENFLEET-B (02595) released its interim performance report, with a net loss of 220 million yuan, a year-on-year narrowing of 68.48%.

GENFLEET-B (02595) announced its interim results for the six months ending June 30, 2026, with revenue of 42.473 million yuan (RMB, same below), a year-on-year decrease of 52.14%; R&D expenses of 193 million yuan, a year-on-year increase of 57.25%; a net loss of 220 million yuan, a year-on-year narrowing of 68.48%; and basic loss per share of 0.59 yuan. The announcement stated that in the first six months of this year (up to June 30), the companys revenue exceeded 42 million yuan, with drug supply revenue increasing nearly sixfold, demonstrating the clinical development potential of the company's pipeline products both domestically and internationally, as well as the company's integrated development capabilities; other revenues and gains exceeded 40 million yuan. As of June 30 this year, cash and bank balances (including cash and cash equivalents, restricted bank deposits, and time deposits with an initial term of more than three months) exceeded 1.784 billion yuan.